-$0.08 Earnings Per Share Expected for LumiraDx Limited (NASDAQ:LMDX) This Quarter

Analysts predict that LumiraDx Limited (NASDAQ:LMDX) will report earnings of ($0.08) per share for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for LumiraDx’s earnings. The company is expected to issue its next quarterly earnings report on Wednesday, February 9th.

According to Zacks, analysts expect that LumiraDx will report full year earnings of $0.13 per share for the current year, with EPS estimates ranging from ($0.02) to $0.28. For the next financial year, analysts forecast that the firm will post earnings of ($0.40) per share, with EPS estimates ranging from ($0.40) to ($0.39). Zacks’ EPS calculations are an average based on a survey of research firms that that provide coverage for LumiraDx.

LumiraDx (NASDAQ:LMDX) last announced its quarterly earnings data on Wednesday, November 10th. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.05. The company had revenue of $109.08 million for the quarter, compared to analyst estimates of $100.84 million.

Several equities analysts have commented on LMDX shares. Evercore ISI began coverage on shares of LumiraDx in a research report on Monday, November 15th. They set an “outperform” rating and a $20.00 target price on the stock. BTIG Research restated a “buy” rating and set a $12.00 price target on shares of LumiraDx in a report on Friday, November 12th. Zacks Investment Research upgraded shares of LumiraDx from a “sell” rating to a “hold” rating in a report on Wednesday. Finally, Raymond James began coverage on shares of LumiraDx in a research note on Monday, October 25th. They issued an “outperform” rating for the company.

Several institutional investors have recently added to or reduced their stakes in the company. UBS Group AG acquired a new position in LumiraDx in the 3rd quarter valued at about $29,000. Morgan Stanley acquired a new position in LumiraDx in the 3rd quarter valued at about $75,000. Geode Capital Management LLC acquired a new position in LumiraDx in the 3rd quarter valued at about $205,000. Jane Street Group LLC acquired a new position in LumiraDx in the 3rd quarter valued at about $224,000. Finally, Citadel Advisors LLC acquired a new position in LumiraDx in the 3rd quarter valued at about $317,000.

NASDAQ LMDX opened at $9.41 on Friday. LumiraDx has a 1-year low of $7.15 and a 1-year high of $11.09. The company has a debt-to-equity ratio of 1.66, a quick ratio of 1.65 and a current ratio of 2.56. The stock has a fifty day moving average of $9.19.

LumiraDx Company Profile

LumiraDx Limited is a point of care diagnostics company. Its testing solutions are being deployed by governments and leading healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools and workplaces to screen, diagnose, and monitor wellness as well as disease. LumiraDx Limited, formerly known as CA Healthcare Acquisition Corp., is based in BOSTON.

See Also: What is the FTSE 100 index?

Get a free copy of the Zacks research report on LumiraDx (LMDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for LumiraDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LumiraDx and related companies with MarketBeat.com's FREE daily email newsletter.